The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects rema...

Celý popis

Podrobná bibliografia

Vydané v:	iScience Ročník 24; číslo 12; s. 103479
Hlavní autori:	Ndeupen, Sonia, Qin, Zhen, Jacobsen, Sonya, Bouteau, Aurélie, Estanbouli, Henri, Igyártó, Botond Z.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 17.12.2021 Elsevier
Predmet:	Biological sciences Biotechnology Immunology Biotechnology Biological sciences Immunology
ISSN:	2589-0042, 2589-0042
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!